388 related articles for article (PubMed ID: 19826111)
1. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera.
Quintás-Cardama A; Kantarjian H; Manshouri T; Luthra R; Estrov Z; Pierce S; Richie MA; Borthakur G; Konopleva M; Cortes J; Verstovsek S
J Clin Oncol; 2009 Nov; 27(32):5418-24. PubMed ID: 19826111
[TBL] [Abstract][Full Text] [Related]
2. Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a.
Quintás-Cardama A; Abdel-Wahab O; Manshouri T; Kilpivaara O; Cortes J; Roupie AL; Zhang SJ; Harris D; Estrov Z; Kantarjian H; Levine RL; Verstovsek S
Blood; 2013 Aug; 122(6):893-901. PubMed ID: 23782935
[TBL] [Abstract][Full Text] [Related]
3. Cepeginterferon alfa-2b in the treatment of chronic myeloproliferative diseases.
Melikyan AL; Subortseva IN; Gilyazitdinova EA; Koloshejnova TI; Pustovaya EI; Egorova EK; Kovrigina AM; Sudarikov AB; Abdullaev AO; Lomaia EG; Siordiya NT; Zaritskey AY; Savchenko VG
Ter Arkh; 2018 Aug; 90(7):23-29. PubMed ID: 30701919
[TBL] [Abstract][Full Text] [Related]
4. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera.
Kiladjian JJ; Cassinat B; Chevret S; Turlure P; Cambier N; Roussel M; Bellucci S; Grandchamp B; Chomienne C; Fenaux P
Blood; 2008 Oct; 112(8):3065-72. PubMed ID: 18650451
[TBL] [Abstract][Full Text] [Related]
5. Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial.
Masarova L; Patel KP; Newberry KJ; Cortes J; Borthakur G; Konopleva M; Estrov Z; Kantarjian H; Verstovsek S
Lancet Haematol; 2017 Apr; 4(4):e165-e175. PubMed ID: 28291640
[TBL] [Abstract][Full Text] [Related]
6. Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea.
Yacoub A; Mascarenhas J; Kosiorek H; Prchal JT; Berenzon D; Baer MR; Ritchie E; Silver RT; Kessler C; Winton E; Finazzi MC; Rambaldi A; Vannucchi AM; Leibowitz D; Rondelli D; Arcasoy MO; Catchatourian R; Vadakara J; Rosti V; Hexner E; Kremyanskaya M; Sandy L; Tripodi J; Najfeld V; Farnoud N; Papaemmanuil E; Salama M; Singer-Weinberg R; Rampal R; Goldberg JD; Barbui T; Mesa R; Dueck AC; Hoffman R
Blood; 2019 Oct; 134(18):1498-1509. PubMed ID: 31515250
[TBL] [Abstract][Full Text] [Related]
7. High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a.
Kiladjian JJ; Cassinat B; Turlure P; Cambier N; Roussel M; Bellucci S; Menot ML; Massonnet G; Dutel JL; Ghomari K; Rousselot P; Grange MJ; Chait Y; Vainchenker W; Parquet N; Abdelkader-Aljassem L; Bernard JF; Rain JD; Chevret S; Chomienne C; Fenaux P
Blood; 2006 Sep; 108(6):2037-40. PubMed ID: 16709929
[TBL] [Abstract][Full Text] [Related]
8. Interferon α-2b gains high sustained response therapy for advanced essential thrombocythemia and polycythemia vera with JAK2V617F positive mutation.
Huang BT; Zeng QC; Zhao WH; Li BS; Chen RL
Leuk Res; 2014 Oct; 38(10):1177-83. PubMed ID: 25069759
[TBL] [Abstract][Full Text] [Related]
9. Interferon alpha therapy in essential thrombocythemia and polycythemia vera-a systematic review and meta-analysis.
Bewersdorf JP; Giri S; Wang R; Podoltsev N; Williams RT; Tallman MS; Rampal RK; Zeidan AM; Stahl M
Leukemia; 2021 Jun; 35(6):1643-1660. PubMed ID: 32868875
[TBL] [Abstract][Full Text] [Related]
10. Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha.
Stauffer Larsen T; Iversen KF; Hansen E; Mathiasen AB; Marcher C; Frederiksen M; Larsen H; Helleberg I; Riley CH; Bjerrum OW; Rønnov-Jessen D; Møller MB; de Stricker K; Vestergaard H; Hasselbalch HC
Leuk Res; 2013 Sep; 37(9):1041-5. PubMed ID: 23827351
[TBL] [Abstract][Full Text] [Related]
11. Pegylated interferon Alfa-2a and hydroxyurea in polycythemia vera and essential thrombocythemia: differential cellular and molecular responses.
Tashi T; Swierczek S; Kim SJ; Salama ME; Song J; Heikal N; King KY; Hickman K; Litton S; Prchal JT
Leukemia; 2018 Aug; 32(8):1830-1833. PubMed ID: 29556018
[No Abstract] [Full Text] [Related]
12. Pegylated interferon for the treatment of early myelofibrosis: correlation of serial laboratory studies with response to therapy.
O'Neill C; Siddiqi I; Brynes RK; Vergara-Lluri M; Moschiano E; O'Connell C
Ann Hematol; 2016 Apr; 95(5):733-8. PubMed ID: 26961933
[TBL] [Abstract][Full Text] [Related]
13. Can pegylated interferon improve the outcome of polycythemia vera patients?
Crisà E; Cerrano M; Beggiato E; Benevolo G; Lanzarone G; Manzini PM; Borchiellini A; Riera L; Boccadoro M; Ferrero D
J Hematol Oncol; 2017 Jan; 10(1):15. PubMed ID: 28086927
[TBL] [Abstract][Full Text] [Related]
14. [Interferon-alpha-2b induces molecular responses of patients with polycythemia vera and its post-polycythemic myelofibrosis].
Bai J; Xue YP; Zhang L; Li CH; Fan DM; Li B; Xu SC; Li DP; Sun XJ; Jiang B; Yang RC
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Apr; 19(2):444-9. PubMed ID: 21518505
[TBL] [Abstract][Full Text] [Related]
15. Limited effects on JAK2 mutational status after pegylated interferon alpha-2b therapy in polycythemia vera and essential thrombocythemia.
Samuelsson J; Mutschler M; Birgegård G; Gram-Hansen P; Björkholm M; Pahl HL
Haematologica; 2006 Sep; 91(9):1281-2. PubMed ID: 16956836
[TBL] [Abstract][Full Text] [Related]
16. Open-label study of oral CEP-701 (lestaurtinib) in patients with polycythaemia vera or essential thrombocythaemia with JAK2-V617F mutation.
Hexner E; Roboz G; Hoffman R; Luger S; Mascarenhas J; Carroll M; Clementi R; Bensen-Kennedy D; Moliterno A
Br J Haematol; 2014 Jan; 164(1):83-93. PubMed ID: 24903629
[TBL] [Abstract][Full Text] [Related]
17. A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis.
Mascarenhas J; Kosiorek H; Prchal J; Yacoub A; Berenzon D; Baer MR; Ritchie E; Silver RT; Kessler C; Winton E; Finazzi MC; Rambaldi A; Vannucchi AM; Leibowitz D; Rondelli D; Arcasoy MO; Catchatourian R; Vadakara J; Rosti V; Hexner E; Kremyanskaya M; Sandy L; Tripodi J; Najfeld V; Farnoud N; Salama ME; Weinberg RS; Rampal R; Goldberg JD; Mesa R; Dueck AC; Hoffman R
Leukemia; 2019 Dec; 33(12):2974-2978. PubMed ID: 31363161
[No Abstract] [Full Text] [Related]
18. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management.
Tefferi A; Barbui T
Am J Hematol; 2020 Dec; 95(12):1599-1613. PubMed ID: 32974939
[TBL] [Abstract][Full Text] [Related]
19. A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life.
Samuelsson J; Hasselbalch H; Bruserud O; Temerinac S; Brandberg Y; Merup M; Linder O; Bjorkholm M; Pahl HL; Birgegard G;
Cancer; 2006 Jun; 106(11):2397-405. PubMed ID: 16639737
[TBL] [Abstract][Full Text] [Related]
20. Data-driven analysis of JAK2V617F kinetics during interferon-alpha2 treatment of patients with polycythemia vera and related neoplasms.
Pedersen RK; Andersen M; Knudsen TA; Sajid Z; Gudmand-Hoeyer J; Dam MJB; Skov V; Kjaer L; Ellervik C; Larsen TS; Hansen D; Pallisgaard N; Hasselbalch HC; Ottesen JT
Cancer Med; 2020 Mar; 9(6):2039-2051. PubMed ID: 31991066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]